Podcast: Tip60: Main functions and its inhibitors

Author: Yepeng Luan

For article details, visit: http://benthamscience.com/journals/mini-reviews-in-medicinal-chemistry/article/145753/

Subscribe our YouTube channelhttp://bit.ly/1lr0czy

Upcoming Thematic Issue – Recent Advances in Cancer Research: Targets and New Ligands

Hottopic- Cpd- Marcela Cristina De Moraes


Press Release for EurekAlert!Chromatin remodeling proteins: New insights in human malignancy and targeted cancer therapy

Beijing, China – Chromatin remodeling proteins (chromatin remodelers) are essential and powerful regulators for critical DNA-templated cellular processes, such as DNA replication, recombination, gene transcription/repression, and DNA damage repair. These molecular and genetic processes are important for a wide spectrum of cellular functions, including cell cycle, death, differentiation, pluripotency, and genome integrity. Recently, many scientific reports have shown that chromatin remodeling proteins could be promising new targets for the treatment of human malignancy.

“This is a hot and exciting research topic for cancer researchers, and our article provides an updated understanding on the functions and mechanisms of chromatin remodelers in human cancers,” says Dr. Chun Zhang, the principle investigator of the Department of Nuclear Medicine of Beijing Chao-Yang Hospital and Capital Medical University of China.

Chromatin remodeling is an energy-driven process in which chromatin remodelers use the energy of ATP hydrolysis to change the nucleosome structure. In human cells, there are four chromatin remodeler families: SWI/SNF, INO80, ISWI and CHD family. Each family of chromatin remodelers has multiple protein members that form a variety of protein complexes. Each chromatin remodeler complex has unique function in regulating gene expression and DNA repair.

“Genes encoding chromatin remodeler proteins are the most frequently mutated genes in human cancer tissues, indicating their tumor suppressive functions and potential therapeutic usages for cancer treatment,” says Dr. Pingyu Zhang from the Department of Gastroenterology, Hepatology and Nutrition at the University of Texas MD Anderson Cancer Center of USA, “We believe that chromatin remodelers will become therapeutic targets for cancer therapies in the future.”

The report is published in the journal Current Protein and Peptide Science. Dr. Jie Lu (Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University) is also involved in this study.

Read the recently published research on “Chromatin remodeling proteins: New insights in human malignancy and targeted cancer therapy” from the Journal “Current Protein & Peptide Science by Dr. Chun Zhang.

Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight

Journal: Current Neuropharmacology

Author(s): Nicolai E. Savaskan, Zheng Fan, Thomas Broggini, Michael Buchfelder and Ilker Y Eyüpoglu.

Affiliation: Department of Neurosurgery, Universitätsklinikum Erlangen, Friedrich Alexander University of Erlangen- Nürnberg (FAU), Schwabachanlage 6, D-91054 Erlangen, Germany

Abstract: Malignant brain tumors are characterized by destructive growth and neuronal cell death making them one of the most devastating diseases. Neurodegenerative actions of malignant gliomas resemble mechanisms also found in many neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases and amyotrophic lateral sclerosis. Recent data demonstrate that gliomas seize neuronal glutamate signaling for their own growth advantage. Excessive glutamate release via the glutamate/cystine antiporter xCT (system xc-, SLC7a11) renders cancer cells resistant to chemotherapeutics and create the tumor microenvironment toxic for neurons. In particular the glutamate/cystine antiporter xCT takes center stage in neurodegenerative processes and sets this transporter a potential prime target for cancer therapy.


Noteworthy is the finding, that reactive oxygen species (ROS) activate transient receptor potential (TRP) channels and thereby TRP channels can potentiate glutamate release. Yet another important biological feature of the xCT/glutamate system is its modulatory effect on the tumor microenvironment with impact on host cells and the cancer stem cell niche. The EMA and FDA-approved drug sulfasalazine (SAS) presents a lead compound for xCT inhibition, although so far clinical trials on glioblastomas with SAS were ambiguous. Here, we critically analyze the mechanisms of action of xCT antiporter on malignant gliomas and in the tumor microenvironment. Deciphering the impact of xCT and glutamate and its relation to TRP channels in brain tumors pave the way for developing important cancer microenvironmental modulators and drugable lead targets.

View the article here: http://benthamscience.com/journals/current-neuropharmacology/volume/13/issue/2/page/258/

World Brain Tumor Day 2016

banner-World Brain Tumor Day

Bentham Science presents the latest articles on Brain Tumor research published in high quality Journals. Find relevant research articles here:




Cancers can be halted with the Gut Bacteria!

Gut bacteria thus far have never been heroic in our stories about health. We have only been concerned how they influence digestion and can potentially harm our dietary habits. Never had we thought that these microorganisms can be the knights in our war against cancer.

E.coli bacteria

Researchers in Roche Holding AG and AstraZeneca Plc are keen in finding the use of gut bacteria to treat different forms of cancer. They have so far helped in retarding the growth of malignant tumors that are destroying the healthy cells. The research is being done on mice and positive results have been noted. The Bifidobacterium, living in the gastrointestinal tract, were tried on skin cancer samples and, much to the delight of the researchers, there appeared to be promise in the study.

Soon the research will be tested for humans suffering from cancer.

Maximising the Value of Imaging in Oncology Drug Development, 12-13 March, London, UK

Maximising the Value of Imaging in Oncology Drug Development, 12-13 March, London, UK

The roll of medical imaging is and will continue to be vital. This must attend event will feature a line-up of leading experts including Novartis, GSK, Roche, Cancer Research UK, TNO and more, providing attendees with insight into the industry and its future.

For more information, please contact Daniel Lee at dlee@smi-online.co.uk

%d bloggers like this: